SyntheticMR publishes the outcome of the rights issue

SyntheticMR completed a rights issue that will provide approximately SEK 32.8 million before issue costs, with subscription 98.6% overall (87.5% with subscription rights, 11.1% without) and guarantee commitments of 417,786 shares (≈1.4% of the offer) being utilized. The company will issue 29,777,342 new shares, increasing share count to 89,332,027 and share capital by SEK 661,056.9924 to SEK 1,983,170.9994, implying ~33.33% dilution; BTAs trade on Spotlight until registration (last expected trading day 23 Feb 2026). Allotment and settlement instructions will be communicated to subscribers and nominees.

Analysis

MARKET STRUCTURE: The rights issue increases shares outstanding from 59.55m to 89.33m (+50% absolute) and dilutes existing holders by ~33.3%, while raising SEK 32.8m pre-costs. Winners: new/active subscribers and the company (short-term runway); losers: passive pre-rights holders who didn’t top-up and short-term liquidity providers (selling pressure). This is not a product/market-share event for medtech competitors but it materially increases free float and downward supply pressure into conversion (BTA conversion expected 23 Feb). Cross-asset: negligible macro FX or bond impact; small-cap Nordic medtech ETFs and illiquid option markets will see the largest flow/volatility effects.

RISK ASSESSMENT: Immediate risks (days): forced selling around BTA conversion and notification/settlement; short-term (weeks/months): realization of proceeds vs. burn rate — if SEK 32.8m covers <6 months of cash burn the company will need another raise (high tail risk). Hidden dependencies: actual operating runway, milestone-driven revenue timing, and insider support (Swedia Invest guarantee used) which concentrates risk. Catalysts to watch: BTA conversion (23 Feb), next monthly cash burn disclosure or Q1 update within 30–90 days, and any new commercial contracts.

TRADE IMPLICATIONS: Direct play: avoid initiating full-sized longs pre-conversion; accumulate only on confirmed post-conversion weakness. If you already own >3% position, participate pro-rata or reduce to 3% to limit dilution exposure. Options: if liquid, buy 3‑month puts with strike ~25% below post-conversion price as downside insurance; otherwise size via limit orders and tight stops. Sector rotation: move marginal capital from micro-cap Nordic medtechs into larger, revenue-positive medical device names or ETFs to reduce idiosyncratic financing risk.

CONTRARIAN ANGLES: Consensus treats this as routine financing — but SEK 32.8m could be meaningful if burn is low (e.g., <SEK 5m/month implies ~6+ months runway), making a post-conversion rebound likely; conversely, if burn >SEK 10m/month the company is re‑financing-prone. Historical parallels: Nordic medtech rights issues that deliver 6–12 month commercial milestones often recover 40–100% from depressed levels; unintended consequence — guarantee usage by Swedia Invest may increase insider concentration and reduce float post-allotment, tightening true tradable supply unexpectedly.

Key Decisions for Investors

• If you own SyntheticMR exposure >3% NAV, reduce to 3% within 10 trading days pre-conversion to limit dilution risk and reserve dry powder for re-entry on post-conversion weakness.
• Do not initiate new large long positions before BTA conversion; instead plan to accumulate up to 2% NAV only if the post-conversion price trades ≥20% below the 5-day pre-rights average within 5–10 trading days after 23 Feb 2026, target 12-month gain 50%, hard stop-loss 30%.
• If exchange-traded options exist, buy 3-month puts with strike ~25% below the post-conversion mid-price (size = 30% of position notional) as hedge; if no options, implement staggered limit buys and 30% stop-loss orders instead.
• Require proof of runway: if company fails to demonstrate ≥6 months additional runway (post-issue) within 60 days or announces another capital raise within 6 months, exit remaining position or initiate a tactical short sized ≤1% NAV.